The company may no longer be operating, as it may be out of business. Find out why through their latest events.
Arix Bioscience Management
Management criteria checks 2/4
Arix Bioscience's CEO is Rob Lyne, appointed in Apr 2021, has a tenure of 2.67 years. total yearly compensation is £701.00K, comprised of 42.8% salary and 57.2% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth £225.31K. The average tenure of the management team and the board of directors is 0.8 years and 2.7 years respectively.
Key information
Rob Lyne
Chief executive officer
UK£701.0k
Total compensation
CEO salary percentage
42.80%
CEO tenure
2.7yrs
CEO ownership
0.2%
Management average tenure
less than a year
Board average tenure
2.7yrs
Recent management updates
Recent updates
CEO Compensation Analysis
How has Rob Lyne's remuneration changed compared to Arix Bioscience's earnings?
Date
Total Compensation
Salary
Company Earnings
Jun 30 2023
n/a
n/a
UK£15m
Mar 31 2023
n/a
n/a
-UK£6m
Dec 31 2022
UK£701k
UK£300k
-UK£28m
Sep 30 2022
n/a
n/a
-UK£40m
Jun 30 2022
n/a
n/a
-UK£53m
Mar 31 2022
n/a
n/a
-UK£57m
Dec 31 2021
UK£442k
UK£188k
-UK£61m
Compensation vs Market: Rob's total compensation ($USD881.57K) is about average for companies of similar size in the UK market ($USD745.86K).
Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.
CEO
Rob Lyne (40 yo)
2.7yrs
Tenure
UK£701,000
Compensation
Mr. Robert Lyne, also known as Rob, is Chief Executive Officer of Arix Bioscience plc from June 2022 and serves as its Director since August 2022 and served as its General Counsel. Mr. Lyne previously serv...
Leadership Team
Name
Position
Tenure
Compensation
Ownership
Robert Lyne
CEO & Director
2.7yrs
UK£701.00k
0.16% £ 225.3k
Tom Davidson
Finance Director
less than a year
no data
no data
Laura Craig
Investor Relations Officer
less than a year
no data
no data
Tassos Konstantinou
Managing Director
less than a year
no data
no data
Jade Fletcher
Financial Controller
less than a year
no data
no data
Felix Breyer
Associate
no data
no data
no data
Roy Bartel-Taverner
Analyst
no data
no data
no data
0.8yrs
Average Tenure
Experienced Management: ARIXL's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Members
Name
Position
Tenure
Compensation
Ownership
Robert Lyne
CEO & Director
2.7yrs
UK£701.00k
0.16% £ 225.3k
Maureen O'Connell
Non-Executive Director
2.7yrs
UK£85.00k
no data
Isaac Kohlberg
Non-Executive Director
2.7yrs
UK£85.00k
no data
Peregrine David Euan Moncreiffe
Independent Non-Executive Chairman
2.7yrs
UK£150.00k
0.58% £ 821.5k
Andrew Smith
Independent Non-Executive Director
1.3yrs
UK£33.00k
no data
Debra Barker
Senior Independent Director
1.3yrs
UK£38.00k
0.040% £ 57.1k
2.7yrs
Average Tenure
61yo
Average Age
Experienced Board: ARIXL's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2023/12/12 00:31
End of Day Share Price
2023/09/14 00:00
Earnings
2023/06/30
Annual Earnings
2022/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Arix Bioscience plc is covered by 9 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.